What is HC Wainwright’s Forecast for SNTI FY2030 Earnings?

Senti Biosciences, Inc. (NASDAQ:SNTI) – Analysts at HC Wainwright issued their FY2030 earnings estimates for Senti Biosciences in a research note issued on Friday, March 27th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.07) for the year. The consensus estimate for Senti Biosciences’ current full-year earnings is ($14.54) per share.

Several other research firms have also issued reports on SNTI. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday. Finally, Chardan Capital decreased their target price on Senti Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Senti Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Senti Biosciences Stock Performance

Shares of NASDAQ:SNTI opened at $0.81 on Monday. Senti Biosciences has a 52-week low of $0.77 and a 52-week high of $5.10. The company has a market capitalization of $25.29 million, a P/E ratio of -0.25 and a beta of 2.12. The company has a 50-day simple moving average of $0.93 and a 200 day simple moving average of $1.37.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $1.00 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in Senti Biosciences during the fourth quarter worth approximately $40,000. Virtu Financial LLC acquired a new position in shares of Senti Biosciences in the fourth quarter valued at approximately $46,000. Citadel Advisors LLC bought a new position in shares of Senti Biosciences during the third quarter worth approximately $117,000. Geode Capital Management LLC increased its stake in shares of Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the period. Finally, Armistice Capital LLC acquired a new stake in Senti Biosciences during the 2nd quarter worth approximately $1,883,000. 25.70% of the stock is owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.